Antiplatelet therapy in patients undergoing primary percutaneous coronary intervention for ST-elevation myocardial infarction: A retrospective observational study of prasugrel and clopidogrel

Cardiovascular Therapeutics

Volumn 32, Issue 1, 2014, Pages 1-6

  Koshy, Aaron ^a   Balasubramaniam, Karthik ^a   Noman, Awsan ^b   Zaman, Azfar G ^a,b  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b FREEMAN HOSPITAL   (United Kingdom)

Author keywords

Clopidogrel; Mortality; Prasugrel; Primary percutaneous coronary intervention; ST elevation myocardial infarction

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEMOGLOBIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRASUGREL;

ADULT; AGED; ARTICLE; BODY WEIGHT; CEREBROVASCULAR ACCIDENT; CLINICAL ASSESSMENT; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DRUG EFFICACY; DRUG SAFETY; FEMALE; HAZARD RATIO; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART RATE; HEMOGLOBIN BLOOD LEVEL; HOSPITAL ADMISSION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MIDDLE AGED; MORTALITY; OBSERVATIONAL STUDY; PERCUTANEOUS CORONARY INTERVENTION; PRIMARY PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; TERTIARY HEALTH CARE; TRANSIENT ISCHEMIC ATTACK; TREATMENT DURATION; TREATMENT OUTCOME;

CLOPIDOGREL; MORTALITY; PRASUGREL; PRIMARY PERCUTANEOUS CORONARY INTERVENTION; ST-ELEVATION MYOCARDIAL INFARCTION;

ADULT; AGED; ELECTROCARDIOGRAPHY; FEMALE; HOSPITAL MORTALITY; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PIPERAZINES; PLATELET AGGREGATION INHIBITORS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; THIOPHENES; TICLOPIDINE;

EID: 84892521176     PISSN: 17555914     EISSN: 17555922     Source Type: Journal    
DOI: 10.1111/1755-5922.12051     Document Type: Article

References (25)

1. Kushner FG, Smith SC, King SB, et al. 2009 focused updates: ACC/AHA guidelines for the management of patients with st-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and acc/aha/scai guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update) a report of the american college of cardiology foundation/american heart association task force on practice guidelines. Circulation 2009;120:2271-2306.
2. Van de Werf F, Bax J, Betriu A, et al. Management of acute myocardial infarction in patients presenting with persistent st-segment elevation. Eur Heart J 2008;29:2909-2945.
3. Eitel I, Franke A, Schuler G, et al. St-segment resolution and prognosis after facilitated versus primary percutaneous coronary intervention in acute myocardial infarction: A meta-analysis. Clin Res Cardiol 2010;99:1-11.
4. Grosgurin O, Plojoux J, Keller PF, et al. Prehospital emergency physician activation of interventional cardiology team reduces door-to-balloon time in st-elevation myocardial infarction. Swiss Med Wkly 2010;140:228-232.
5. Yeghiazarians Y, Braunstein JB, Askari A, et al. Medical progress: Unstable angina pectoris. N Engl J Med 2000;342:101-114.
6. Le May MR, Dionne R, Maloney J, et al. The role of paramedics in a primary pci program for st-elevation myocardial infarction. Prog Cardiovasc Dis 2010;53:183-187.
7. Prati F, Petronio S, Van Boven AJ, et al. Evaluation of infarct-related coronary artery patency and microcirculatory function after facilitated percutaneous primary coronary angioplasty the finesse-angio (facilitated intervention with enhanced reperfusion speed to stop events-angiographic) study. JACC Cardiovasc Interv 2010;3:1284-1291.
8. Wijns W, Kolh P. Guidelines on myocardial revascularization the task force on myocardial revascularization of the european society of cardiology (esc) and the european association for cardio-thoracic surgery (eacts). Eur Heart J 2010;31:2501-2555.
9. Montalescot G, Wiviott SD, Brounwald E, et al. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for st-elevation myocardial infarction (triton-timi 38): Double-blind, randomised controlled trial. Lancet 2009;373:723-731.
10. Morrow DA, Antman EM, Parsons L, et al. Application of the timi risk score for st-elevation mi in the national registry of myocardial infarction 3. JAMA 2001;286:1356-1359.
11. Heggunje PS, Harjai KJ, Stone GW, et al. Procedural success versus clinical risk status in determining discharge of patients after primary angioplasty for acute myocardial infarction. J Am Coll Cardiol 2004;44:1400-1407.
12. Antoniucci D, Rodriguez A, Hempel A, et al. A randomized trial comparing primary infarct artery stenting with or without abciximab in acute myocardial infarction. J Am Coll Cardiol 2003;42:1879-1885.
13. Brener SJ, Barr LA, Burchenal JEB, et al. Randomized, placebo-controlled trial of platelet glycoprotein iib/iiia blockade with primary angioplasty for acute myocardial infarction. Circulation 1998;98:734-741.
14. Montalescot G, Barragan P, Wittenberg O, et al. Platelet glycoprotein iib/iiia inhibition with coronary stenting for acute myocardial infarction. N Engl J Med 2001;344:1895-1903.
15. Neumann FJ, Kastrati A, Schmitt C, et al. Effect of glycoprotein iib/iiia receptor blockade with abciximab on clinical and angiographic restenosis rate after the placement of coronary stents following acute myocardial infarction. J Am Coll Cardiol 2000;35:915-921.
16. Stone GW, Grines CL, Cox DA, et al. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med 2002;346:957-966.
17. Maree AO, Fitzgerald DJ. Variable platelet response to aspirin and clopidogrel in atherothrombotic disease. Circulation 2007;115:2196-2207.
18. Montalescot G, Sideris G, Meuleman C, et al. A randomized comparison of high clopidogrel loading doses in patients with non-st-segment elevation acute coronary syndromes - the albion (assessment of the best loading dose of clopidogrel to blunt platelet activation, inflammation and ongoing necrosis) trial. J Am Coll Cardiol 2006;48:931-938.
19. Patti G, Colonna G, Pasceri V, et al. Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention - results from the armyda-2 (antiplatelet therapy for reduction of myocardial damage during angioplasty) study. Circulation 2005;111:2099-2106.
20. von Beckerath N, Taubert D, Pogatsa-Murray G, et al. Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel - results of the isar-choice (intracoronary stenting and antithrombotic regimen: Choose between 3 high oral doses for immediate clopidogrel effect) trial. Circulation 2005;112:2946-2950.
21. Wolfram RM, Torguson RL, Hassani SE, et al. Clopidogrel loading dose (300 versus 600 mg) strategies for patients with stable angina pectoris subjected to percutaneous coronary intervention. Am J Cardiol 2006;97:984-989.
22. Agewall S, Badimon L, Drouet L, et al. Oral antiplatelet agents in acs: From pharmacology to clinical differences. Fundam Clin Pharmacol 2011;25:564-571.
23. Wilson W, Gurvitch R, Ajani AE. Prasugrel: A novel platelet adp p2y (12) receptor antagonist. Cardiovasc Ther 2009;27:194-198.
24. Wiviott SD, Trenk D, Frelinger AL, et al. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention - the prasugrel in comparison to clopidogrel for inhibition of platelet activation and aggregation-thrombolysis in myocardial infarction 44 trial. Circulation 2007;116:2923-2932.
25. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001-2015.